TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3514075

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 93
Study: 3396372

Group type: EXPERIMENTAL
Intervention: Kinetic treatment table
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional bed
Number of subjects: 65
Study: 31694732

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quaternary ammonia or biguanide disinfectant
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultraviolet germicidal irradiation (UVGI)
Number of subjects: 30
Study: 29533115

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2,000 IU daily with standard chemotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 72
Study: 28152221

Group type: EXPERIMENTAL
Intervention: Stoma cloths
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HMEs with stoma cloths
Number of subjects: 18
Study: 26314808

Group type: EXPERIMENTAL
Intervention: Positive skin-prick test (SPT) for aeroallergens
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis (AD) diagnosis
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Positive SPT for aeroallergens
Number of subjects: 1583
Study: 23423452

Group type: EXPERIMENTAL
Intervention: Etiquette-based medicine (EtBM) behaviors performed by hospitalists
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Sitting down during patient interaction
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Etiquette-based medicine scores
Number of subjects: 226
Study: 21219197

Group type: EXPERIMENTAL
Intervention: Oral amino acid supplementation (4 g thrice a day) for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 18421537

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 113
Study: 16531445

Group type: EXPERIMENTAL
Intervention: Ketamine (i.v. 250 microg kg(‐1))
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 54
Study: 12562650

Group type: EXPERIMENTAL
Intervention: Idoxifene
Number of subjects: 321

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 321
Study: 10946983

Group type: EXPERIMENTAL
Intervention: High-oxygen-permeable soft lens (CIBAVision Focus/NIGHT & DAY, Dk/t= 175)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no lens)
Number of subjects: 2
Study: 9140792

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Enalapril (10-20 mg)
Number of subjects: 34
Study: 1580094

Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides 500 mg (normal volunteers)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides 1000 mg (patients with venous hypertension and diabetic microangiopathy)
Number of subjects: 59
Study: 3907343

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid and tobramycin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Piperacillin, tobramycin, and vancomycin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 50
Study: 29667902

Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: conventional blood cardioplegia
Number of subjects: 60
Study: 27317617

Group type: EXPERIMENTAL
Intervention: Taste Lessons Vegetable Menu (TLVM: TL with 3 added experiential learning activities)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Taste Lessons (TL: 5 lessons)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Taste Lessons Vegetable Menu (TLVM)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study: 24290404

Group type: EXPERIMENTAL
Intervention: Individualised pelvic floor muscle training
Number of subjects: 447

Group type: COMPARATOR
Intervention: Prolapse lifestyle advice leaflet and no muscle training (control group)
Number of subjects: 447
Study: 22434360

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo plus cisplatin (75 mg/m2)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo-cisplatin
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin (performance status 0 or 1)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo-cisplatin (performance status 0 or 1)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin (oropharyngeal cancers)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo-cisplatin (oropharyngeal cancers)
Number of subjects: 795
Study: 21046369

Group type: COMPARATOR
Intervention: Anodal direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathodal direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre stimulation
Number of subjects: 0
Study: 17934839

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 15976248

Group type: EXPERIMENTAL
Intervention: Gargling with sodium azulene sulfonate (Azunol) 4 mg diluted with 100 mL tap water (40 microg/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gargling with tap water (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gargling with sodium azulene sulfonate (Azunol)
Number of subjects: 40
Study: 11466189

Group type: EXPERIMENTAL
Intervention: 150 microg fluticasone twice daily (group F)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 52
Study: 9738225

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (5 x 3.3 Gy irradiation)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 93
Study: 8032826

Group type: EXPERIMENTAL
Intervention: Education package (test group)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no education package)
Number of subjects: 124
Study: 2604508

Group type: EXPERIMENTAL
Intervention: Prophylactic doses of vitamin D during the first 3 months of LT4 treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: No vitamin D during the first 3 months of LT4 treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 19
Study: 31331577

Group type: EXPERIMENTAL
Intervention: MA+SSRIs
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: EA+SSRIs
Number of subjects: 477

Group type: COMPARATOR
Intervention: SSRIs alone
Number of subjects: 477
Study: 28385154

Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) treatment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Second dose of PZQ
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Re-infection rates
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Incidence rate
Number of subjects: 320
Study: 26815880

Group type: EXPERIMENTAL
Intervention: MR‐proANP levels in the high normal range
Number of subjects: 2243
Study: 24518967

Group type: EXPERIMENTAL
Intervention: Palisade sacroiliac joint radiofrequency neurotomy (PSRN)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Celecoxib (400 mg/day for 24 weeks)
Number of subjects: 155
Study: 21983370

Group type: EXPERIMENTAL
Intervention: Bevel-down approach (n = 169)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Bevel-up approach (n = 169)
Number of subjects: 338
Study: 19754867

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment (twice weekly as maintenance treatment)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Emollient vehicle (standard treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment (twice daily during OLP)
Number of subjects: 257
Study: 17973696

Group type: EXPERIMENTAL
Intervention: 4-day training program on essential newborn care for doctors, nurses, and midwives in two hospitals
Number of subjects: 892

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 892
Study: 15365536

Group type: EXPERIMENTAL
Intervention: S. aureus colonization in CRS
Number of subjects: 232

Group type: COMPARATOR
Intervention: S. aureus colonization in control subjects
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Facultative pathogens in CRS
Number of subjects: 232

Group type: COMPARATOR
Intervention: Facultative pathogens in control subjects
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Airway symptoms in CRS
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Respiratory tract infections in CRS
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: S. aureus colonization and severity of symptoms
Number of subjects: 232
Study: 11591950

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 40
Study: 9586877

Group type: EXPERIMENTAL
Intervention: CMF(P)TH
Number of subjects: 195

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 195
Study: 7988813

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g intravenous infusion 15 minutes before ERCP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 100
Study: 2686711

Group type: EXPERIMENTAL
Intervention: Dilevalol twice daily (N = 55)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Dilevalol once daily (N = 40)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Propranolol (N = 53)
Number of subjects: 172
Study: 30881904

Group type: EXPERIMENTAL
Intervention: Isoflurane 1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.2%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5%
Number of subjects: 90
Study: 28279843

Group type: EXPERIMENTAL
Intervention: Experiential exposure to texting while walking in a virtual reality environment
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (not exposed to the intervention)
Number of subjects: 219
Study: 25858103

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with tamoxifen
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hormone therapy (HT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hormone therapy (HT) plus chemotherapy (CT)
Number of subjects: 5
Study: 23460569

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study: 21527905

Group type: EXPERIMENTAL
Intervention: Trans-warmer mattress (TWM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 19878781

Group type: EXPERIMENTAL
Intervention: Nonsteroidal cream (Promiseb Topical Cream)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Desonide cream 0.05%
Number of subjects: 77
Study: 16872785

Group type: EXPERIMENTAL
Intervention: Therapeutic play intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Routine information preparation (Control)
Number of subjects: 203
Study: 15482086

Group type: EXPERIMENTAL
Intervention: Motivational telephone intervention plus self-help workbook
Number of subjects: 67

Group type: COMPARATOR
Intervention: Self-help workbook only
Number of subjects: 67
Study: 11794547

Group type: EXPERIMENTAL
Intervention: Mood and Feelings Questionnaire (MFQ)
Number of subjects: 2560
Study: 8733329

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate bid at a dose of 25/3.6mg/kg/day for 7 days
Number of subjects: 437

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate tid at a dose of 20/5mg/kg/day for 7 days
Number of subjects: 437
Study: 2253536

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally four times a day
Number of subjects: 12
Study: 7001486

Group type: EXPERIMENTAL
Intervention: 150 mg protacine, 3-times daily, orally, for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50 mg indomethacin, 3-times daily, orally, for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 mg protacine, 3-times daily, orally, for 18 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone, 3-times daily, orally, for 18 days
Number of subjects: 40
Study: 30006887

Group type: EXPERIMENTAL
Intervention: Sleep-deprived group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline (after a full night of sleep)
Number of subjects: 0
Study: 30087016

Group type: EXPERIMENTAL
Intervention: Animal Fun program
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control group (normal curriculum)
Number of subjects: 511
Study: 28365372

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: COMPARATOR
Intervention: Opioid blockade (naloxone)
Number of subjects: 191
Study: 25885657

Group type: EXPERIMENTAL
Intervention: Nutrition, physical activity, and healthy weight intervention for 50-69 year-olds.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Wait-listed control group (no intervention).
Number of subjects: 500
Study: 24655694

Group type: EXPERIMENTAL
Intervention: Targeted provider feedback intervention (quarterly reports on BP control rates)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Targeted provider feedback intervention
Number of subjects: 3000
Study: 22453003

Group type: EXPERIMENTAL
Intervention: Acarbose (150 or 300 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no acarbose)
Number of subjects: 44
Study: 20038734

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel and capecitabine (HTX)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (HT)
Number of subjects: 222
Study: 19094763

Group type: EXPERIMENTAL
Intervention: Triptorelin 11.25 mg (one injection)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Triptorelin 3.75 mg (three injections at 28-day intervals)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 127
Study: 15961681

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (0.16 micromol/kg min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 0
Study: 12626215

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg daily plus estradiol valerate 2 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus estradiol valerate 2 mg daily
Number of subjects: 50
Study: 10050868

Group type: COMPARATOR
Intervention: 500 mg oltipraz weekly
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 125 mg oltipraz daily
Number of subjects: 234
Study: 8927288

Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg/day for six months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1361968

Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study: 6507769

Group type: EXPERIMENTAL
Intervention: Fructose‐1,6‐diphosphate (FDP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline solution (sal)
Number of subjects: 39
Study: 31213040

Group type: EXPERIMENTAL
Intervention: 5 mL/h BEI + 10 mL/h PIEB
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5 mL/h BEI of levobupivacaine 0.125% plus fentanyl 1.45 µg/mL (standard group)
Number of subjects: 120
Study: 30423955

Group type: EXPERIMENTAL
Intervention: Flavonoid supplementation (329 mg/day) with 45-minute walking (62.2 +/- 0.9% VO2max)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo with 45-minute walking (62.2 +/- 0.9% VO2max)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Runners ingested a double flavonoid dose (658 mg/day) and ran for 2.5 h (69.2 +/- 1.2% VO2max)
Number of subjects: 96
Study: 26164110

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) plus pharmacotherapy
Number of subjects: 176
Study: 25098661

Group type: EXPERIMENTAL
Intervention: Hinged ankle braces (2 models)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nonhinged ankle brace
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control condition (no brace)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hinged models
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nonhinged brace
Number of subjects: 17
Study: 22472272

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 27
Study: 20335369

Group type: EXPERIMENTAL
Intervention: CERA 6.3 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CERA 9 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CERA 12 μg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darbepoetin alfa (6.75 μg/kg every 3 weeks or 2.25 μg/kg weekly)
Number of subjects: 0
Study: 17926466

Group type: EXPERIMENTAL
Intervention: Leflunomide (LF) 100 mg/day for 3 days then 20 mg/day for 6 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Leflunomide (LF)
Number of subjects: 58
Study: 15602683

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study: 11943259

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg plus Vitamin E 400 IU, each twice daily (n=19)
Number of subjects: 40
Study: 9794352

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily for 8 weeks
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg once daily for 8 weeks
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 7892448

Group type: EXPERIMENTAL
Intervention: SPIO-enhanced SE and FLASH sequences
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unenhanced T2-weighted SE sequences
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unenhanced images
Number of subjects: 15
Study: 2128265

Group type: EXPERIMENTAL
Intervention: 10% Intralipid (MCT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% Lipofundin (LCT)
Number of subjects: 20
Study: 110184

Group type: EXPERIMENTAL
Intervention: RIF 600 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: RIF 750 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: RIF 450 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: RIF-EMB therapy (300 mg INH and 15 mg EMB per kg)
Number of subjects: 822

Group type: COMPARATOR
Intervention: 12 months of chemotherapy after sputum conversion
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: RIF-INH therapy
Number of subjects: 822
Study: 31492784

Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Low-intensity exercise programme (control)
Number of subjects: 160
Study: 27628062

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2.0 mg) administered as three monthly doses followed by injections every 2 months
Number of subjects: 40
Study: 25827058

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO, 15 mg for 6 weeks, then 30 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 42
Study: 24246211

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg daily plus celecoxib 200 mg daily (study group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Doxazosin 4 mg daily alone (control group)
Number of subjects: 82
Study: 21575919

Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg, n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg, n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg) + Verapamil (180 mg, n=10)
Number of subjects: 30
Study: 19627355

Group type: EXPERIMENTAL
Intervention: Tin-containing fluoride solutions (400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tin-containing fluoride solutions (1,400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tin-containing fluoride solutions (2,100 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control group (no treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test solutions without demineralization (twice daily)
Number of subjects: 0
Study: 16417535

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at doses up to 2000 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15573840

Group type: EXPERIMENTAL
Intervention: Spectacles lenses with a prismatic correction of low power (5‐7 prismatic dioptres) in the better eye
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no prismatic correction)
Number of subjects: 28
Study: 11244453

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO(2max), n=7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (70% VO(2max), n=8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-exercising control group (n=8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lean subjects (n=6)
Number of subjects: 23
Study: 9135350

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 102

Group type: COMPARATOR
Intervention: propofol
Number of subjects: 102
Study: 8193987

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone 1.5 mg/kg infused over 5 mins
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-tilt measurements
Number of subjects: 10
Study: 2822924

Group type: EXPERIMENTAL
Intervention: Intraarticular deferoxamine 100 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29913174

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg, initiated at 13-25 weeks' gestation)
Number of subjects: 2543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2543
Study: 27771739

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 220
Study: 24845164

Group type: EXPERIMENTAL
Intervention: Marijuana eCHECKUP TO GO
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study: 23294659

Group type: EXPERIMENTAL
Intervention: Resonant breathing biofeedback training (5 weekly sessions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36